DrugDev President and CEO Ibraheem “Ibs” Mahmood Named to The Medicine Maker International Power 100, Honored as Tech Disruptor by the Philadelphia Business Journal
Recognized for transforming the clinical trials industry by promoting collaboration, standardization and a beautiful technology experience for sponsors, CROs, investigators and patients.
DrugDev President and CEO Ibraheem “Ibs” Mahmood continues to earn accolades for his success in changing the way the pharmaceutical industry conducts clinical trials. This month Ibs was named No. 20 on The Medicine Maker Power 100 list of the world’s most influential people in pharma, and he was honored as a Tech Disruptor by the Philadelphia Business Journal.
Stephanie Sutton, Editor of The Medicine Maker, said, “We’re delighted to welcome Ibs Mahmood to the Power List and to recognize his entrepreneurial thinking and passion to move the clinical trials industry forward through the adoption of new technologies and processes that enable pharma to do more clinical trials.”
Craig Ey, Editor of the Philadelphia Business Journal, said, “Ibs Mahmood represents the spirit of groundbreaking leadership that makes our region a center of pharmaceutical innovation. We’re pleased to honor him as one of this year’s Tech Disruptors.”
DrugDev Executive Chairman Hugo Stephenson MD commented, “There’s a lot of talk about the need to change the way pharma conducts clinical trials, but Ibs convinces pharma to do it. He’s a force of nature, he’s absolutely committed to bringing clinical trials into the modern age, and he’s having a profound impact on drug development. I can’t think of anyone more deserving than Ibs to receive these honors.”
Ibs adds this achievement to a growing list of accolades including being named as one of the PharmaVOICE 100 most inspiring people in life sciences, being a finalist for the international SCRIP CEO of the Year award, and winning the PM360 ELITE award for disrupting the pharmaceutical industry.
Ibs Mahmood said,“It’s a sincere honor to see my name among the same pages as so many distinguished pharmaceutical leaders – and I’d also like to congratulate Dalvir Gill in particular, in recognition of the revolutionary work he’s doing with our valued partner TransCelerate. What’s truly humbling is knowing that this honor was bestowed to all of those featured in this issue by our peers in the industry. I’m beyond grateful, and I promise to continue to use whatever influence I may have to share DrugDev’s passion for delivering clinical trial technology that ultimately helps sponsors improve care for many millions of patients worldwide. That’s what lifts me up every day.”
DrugDev’s unified clinical suite enables sponsors, CROs and sites to do more trials through industry-wide collaboration, standardization and a beautiful technology experience. Featuring solutions for global site payments, site identification and activation, workflow optimization, learning management, and site and patient engagement, DrugDev helps companies transform the quality and efficiency of clinical trials from startup through closeout. The company also powers the revolutionary TransCelerate Investigator Registry and Investigator Databank collaborations with the universal identifier known as the DrugDev Golden Number. Learn why 9 of the top 10 sponsors and 4 of the top 5 CROs trust DrugDev technology at drugdev.com.